Kohei Shitara, MD, National Cancer Center Hospital East

Kohei Shitara, MD, discusses optimizing treatment strategies and addressing unmet needs in resectable gastric and gastroesophageal junction cancers.

Kohei Shitara, MD, discusses efficacy data from a trial of the CAR T-cell therapy satri-cel in advanced gastric/ GEJ adenocarcinoma and pancreatic cancer.

Kohei Shitara, MD, details the mechanisms of action of the investigational therapies domvanalimab and zimberelimab for gastrointestinal cancer.

Expert investigators in GI cancers share their perspectives on the most significant updates in the space shared during the 2025 ASCO Annual Meeting.

Kohei Shitara, MD, discusses the background of the phase 3 CheckMate 649 study in advanced gastric cancer, GEJ cancer, and esophageal adenocarcinoma.

Kohei Shitara, MD, discusses the evaluation of the combination of zolbetuximab plus mFOLFOX6 in patients with CLDN18.2–positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

Kohei Shitara, MD, discusses the rationale for the phase 3 DESTINY-Gastric04 trial in patients with HER2-positive gastric cancer or gastro-esophageal junction adenocarcinoma.

Kohei Shitara, MD, discusses the rationale to analyze the effects of prior therapy on outcomes with TAS-102 in patients with metastatic gastric/gastroesophageal junction cancer.

Kohei Shitara, MD, discusses the FDA approval of fam-trastuzumab deruxtecan-nxki in HER2-positive metastatic gastric/gastroesophageal junction cancer.